Metex 17.5 mg Norveç - Norveççe - Statens legemiddelverk

metex 17.5 mg

medac - gesellschaft für klinische spezialpräparate gmbh - wedel - metotreksatdinatrium - injeksjonsvæske, oppløsning i ferdigfylt penn - 17.5 mg

Metex 20 mg Norveç - Norveççe - Statens legemiddelverk

metex 20 mg

medac - gesellschaft für klinische spezialpräparate gmbh - wedel - metotreksatdinatrium - injeksjonsvæske, oppløsning i ferdigfylt penn - 20 mg

Metex 22.5 mg Norveç - Norveççe - Statens legemiddelverk

metex 22.5 mg

medac - gesellschaft für klinische spezialpräparate gmbh - wedel - metotreksatdinatrium - injeksjonsvæske, oppløsning i ferdigfylt penn - 22.5 mg

Metex 25 mg Norveç - Norveççe - Statens legemiddelverk

metex 25 mg

medac - gesellschaft für klinische spezialpräparate gmbh - wedel - metotreksatdinatrium - injeksjonsvæske, oppløsning i ferdigfylt penn - 25 mg

Metex 30 mg Norveç - Norveççe - Statens legemiddelverk

metex 30 mg

medac - gesellschaft für klinische spezialpräparate gmbh - wedel - metotreksatdinatrium - injeksjonsvæske, oppløsning i ferdigfylt penn - 30 mg

Metex 50 mg/ ml Norveç - Norveççe - Statens legemiddelverk

metex 50 mg/ ml

2care4 aps - metotreksatdinatrium - injeksjonsvæske, oppløsning - 50 mg/ ml

Metex 50 mg/ ml Norveç - Norveççe - Statens legemiddelverk

metex 50 mg/ ml

2care4 aps - metotreksatdinatrium - injeksjonsvæske, oppløsning - 50 mg/ ml

Brukinsa Avrupa Birliği - Norveççe - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Rhesonativ 625 IE/ ml Norveç - Norveççe - Statens legemiddelverk

rhesonativ 625 ie/ ml

octapharma as - immunglobulin anti-d, humant - injeksjonsvæske, oppløsning - 625 ie/ ml

Flebogamma DIF (previously Flebogammadif) Avrupa Birliği - Norveççe - EMA (European Medicines Agency)

flebogamma dif (previously flebogammadif)

instituto grifols s.a. - humant normalt immunglobulin - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - immune sera og immunglobuliner, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.